Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages 525-532

  Lucatello, Barbara ^a   Benso, Andrea ^a   Tabaro, Isabella ^a   Capello, Elena ^a   Caprino, Mirko Parasiliti ^a   Marafetti, Lisa ^b   Rossato, Denis ^c   Oleandri, Salvatore E ^d   Ghigo, Ezio ^a   Maccario, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b ASL Torino 5   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Division of Endocrinology and Metabolism   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FLUDROCORTISONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; RENIN;

ADULT; AGED; ALDOSTERONE RELEASE; ARTICLE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; MALE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SODIUM RESTRICTION; TREATMENT DURATION;

ADULT; AGED; ALDOSTERONE; CROSS-SECTIONAL STUDIES; FEMALE; FLUDROCORTISONE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; MINERALOCORTICOIDS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875141808     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0912     Document Type: Article

References (23)

1. Viera AJ & Neutze DM. Diagnosis of secondary hypertension: an age-based approach. American Family Physician 2010 82 1471-1478.
2. Young WF Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003 144 2208-2213. (doi:10.1210/en.2003- 0279)
3. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario Met al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 2006 48 2293-2300. (doi:10.1016/j.jacc.2006. 07.059)
4. Biglieri EG. Primary aldosteronism due to primary adrenal hyperplasia. In The Adrenal Gland and Hypertension, pp 353-356. Eds F Mantero, EG Biglieri, JW Funder & B Scoggins, New York: Raven Press, 1985.
5. Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension 2004 22 863-869. (doi:10.1097/00004872- 200405000-00001)
6. Irony I, Biglieri EG & Kater CE. The adrenocortical hormones in hypertensive disorders. In Endocrine Mechanism in Hypertension, pp 1-18. Eds JH Laragh, BM Brenner & NM Katler, New York: Raven Press, 1989.
7. Pozzan GB, Armanini D, Cecchetto G, Opocher G, Rigon F, Fassina A & Zacchello F. Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. Journal of Endocrinological Investigation 1997 2 86-89.
8. Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N & Sartorato P. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. Journal of Endocrinological Investigation 2005 28 236-240.
9. Armanini D, Fiore C & Pellati D. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension 2007 50 e69-e70. (doi:10.1161/HYPERTENSIONAHA.107.096925)
10. Fischer E, Beuschlein F, Degenhart C, Jung P, Bidlingmaier M & Reincke M. Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry. Clinical Endocrinology 2012 76 473-477. (doi:10.1111/j.1365-2265.2011.04243.x)
11. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM & Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10.1210/jc.2008-0104)
12. Gordon RD. Primary aldosteronism. Journal of Endocrinological Investigation 1995 18 495-511.
13. Yoneda T, Demura M, Takata H, Kometani M, Karashima S, Yamagishi M & Takeda Y. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. Journal of Clinical Endocrinology and Metabolism 2012 97 1109-1113. (doi:10.1210/jc.2011-2563)
14. Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F & Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2006 91 2618-2623. (doi:10.1210/jc.2006-0078)
15. Mantero F, Armanini D & Urbani S. Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension. Clinical Science and Molecular Medicine. Supplement 1973 45 219S-224S.
16. Cohn D, Jackson RV & Gordon RD. Factors affecting the frequency of occurrence of spironolactone bodies in aldosteronomas and non-tumorous cortex. Pathology 1983 15 273-277. (doi:10.3109/00313028309083505)
17. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR & van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004 136 1227-1235. (doi:10.1016/j.surg.2004.06.051)
18. Tsunoda K, Abe K, Goto T, Yasujima M, Sato M, Omata K, Seino M & Yoshinaga K. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. Journal of Clinical Endocrinology and Metabolism 1986 62 384-389. (doi:10.1210/jcem-62-2-384)
19. Belmin J, Lévy BI & Michel JB. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs & Aging 1994 5 391-400. (doi:10.2165/00002512-199405050-00007)
20. Lim PO, Young WF & MacDonald TM. A review of the medical treatment of primary aldosteronism. Journal of Hypertension 2001 19 353-361. (doi:10.1097/00004872-200103000-00001)
21. Stowasser M. Update in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2009 94 3623-3630. (doi:10.1210/jc.2009-1399)
22. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, ReinckeM& Bidlingmaier M. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassay with and without extraction steps. Clinical Chemistry 2006 52 1749-1755. (doi:10.1373/clinchem.2006.068502)
23. Tomaschitz A & Pilz S. Aldosterone to renin ratio - a reliable screening tool for primary aldosteronism? Hormone and Metabolic Research 2010 42 382-391. (doi:10.1055/s-0030-1248326)